Quarterly report [Sections 13 or 15(d)]

REVENUES (Tables)

v3.25.2
REVENUES (Tables)
6 Months Ended
Jun. 30, 2025
REVENUES  
Schedule of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended June 30, 

​

Six Months Ended June 30, 

​

​

2025

    

2024

​

2025

    

2024

Product sales:

​

​

​

​

​

​

​

​

​

​

​

​

Gross product sales

​

$

79,692

​

$

48,980

​

$

139,884

​

$

87,406

Discounts and allowances

​

​

(20,744)

​

​

(15,530)

​

​

(37,386)

​

​

(27,953)

Total product sales, net

​

​

58,948

​

​

33,450

​

​

102,498

​

​

59,453

Revenues from collaborations:

​

​

​

​

​

​

​

​

​

​

​

​

Release of cost share liability

​

​

39,981

​

​

—

​

​

39,981

​

​

—

Milestone revenue

​

​

—

​

​

—

​

​

3,000

​

​

—

Delivery of drug supplies, royalty and others

​

​

2,756

​

​

3,391

​

​

9,539

​

​

6,922

Total revenues from collaborations

​

​

42,737

​

​

3,391

​

​

52,520

​

​

6,922

Total revenues

​

$

101,685

​

$

36,841

​

$

155,018

​

$

66,375

Schedule of product revenue allowance and reserve categories

The following tables summarize the activities in chargebacks, discounts and fees, government and other rebates and returns that were accounted for within revenue reserves and refund liability, for each of the periods presented (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Chargebacks,

​

Government

​

​

​

​

​

​

Discounts and

​

and Other

​

​

​

​

​

​

Fees

​

Rebates

​

Returns

​

Total

Balance as of January 1, 2025

    

$

13,374

​

$

8,343

​

$

4,723

​

$

26,440

Provision related to current period sales

​

​

28,209

​

​

8,082

​

​

923

​

​

37,214

Adjustment related to prior period sales

​

​

—

​

​

(169)

​

​

(560)

​

​

(729)

Credit or payments made during the period

​

​

(28,624)

​

​

(4,642)

​

​

(157)

​

​

(33,423)

Balance as of June 30, 2025

 

$

12,959

​

$

11,614

​

$

4,929

​

$

29,502

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Chargebacks,

​

Government

​

​

​

​

​

​

​

​

Discounts and

​

and Other

​

​

​

​

​

​

​

​

Fees

​

Rebates

​

Returns

​

Total

Balance as of January 1, 2024

    

$

8,236

​

$

3,517

​

$

3,931

​

$

15,684

Provision related to current period sales

​

​

21,770

​

​

5,259

​

​

522

​

​

27,551

Credit or payments made during the period

​

​

(20,165)

​

​

(4,441)

​

​

(82)

​

​

(24,688)

Balance as of June 30, 2024

 

$

9,841

​

$

4,335

​

$

4,371

​

$

18,547

Schedule of revenues from product sales disaggregated by customers

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended June 30, 

​

Six Months Ended June 30, 

​

​

2025

    

2024

​

2025

    

2024

McKesson Corporation

​

​

31%

​

​

49%

​

​

35%

​

​

46%

Cencora, Inc.

​

​

12%

​

​

20%

​

​

15%

​

​

21%

Cardinal Health, Inc.

​

​

*

​

​

21%

​

​

*

​

​

22%

Lilly

​

​

39%

​

​

—

​

​

26%

​

​

—